Induction of cell fusion/apoptosis in anaplastic thyroid carcinoma in orthotopic mouse model by urokinase-specific oncolytic Sendai virus

Yoshihiro Miyagawa, Koji Araki, Taku Yamashita, Shingo Tanaka, Yuya Tanaka, Masayuki Tomifuji, Yasuji Ueda, Yoshikazu Yonemitsu, Hideaki Shimada, Akihiro Shiotani

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Background: This study was designed to assess the therapeutic effect of urokinase-targeted recombinant oncolytic Sendai virus, termed “BioKnife,” on anaplastic thyroid carcinoma (ATC). Methods: Urokinase activity was investigated in human ATC cell lines, and BioKnife cytotoxicity against the cell lines was evaluated in vitro. Orthotopic mouse models of ATC were treated with three intratumoral injections of BioKnife, control virus, or phosphate-buffered saline (PBS) and were observed daily until >20% weight loss occurred. Results: All three ATC cell lines showed a high level of urokinase activity. BioKnife induced urokinase-dependent cell fusion and cytotoxicity in all cell lines. Orthotopic models treated with BioKnife showed significantly prolonged survival compared with models treated with control virus or PBS (BioKnife 41.6 ± 15.0, control virus 17.0 ± 2.9, PBS 17.7 ± 6.3 days). Conclusions: BioKnife exerted therapeutic effects in orthotopic ATC mouse models. Thus, BioKnife represents a possible treatment option for ATC.

Original languageEnglish
Pages (from-to)2873-2882
Number of pages10
JournalHead and Neck
Volume41
Issue number9
DOIs
Publication statusPublished - Sep 2019

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Fingerprint Dive into the research topics of 'Induction of cell fusion/apoptosis in anaplastic thyroid carcinoma in orthotopic mouse model by urokinase-specific oncolytic Sendai virus'. Together they form a unique fingerprint.

Cite this